Immunic, Inc. (IMUX)
13.11
+0.35
(+2.74%)
USD |
NASDAQ |
Sep 04, 16:00
12.85
-0.26
(-1.98%)
After-Hours: 20:00
Immunic Research and Development Expense (Quarterly) : 25.93M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.93M |
| March 31, 2026 | 25.63M |
| December 31, 2025 | 19.07M |
| September 30, 2025 | 20.01M |
| June 30, 2025 | 21.37M |
| March 31, 2025 | 21.53M |
| December 31, 2024 | 21.62M |
| September 30, 2024 | 21.37M |
| June 30, 2024 | 18.32M |
| March 31, 2024 | 18.74M |
| December 31, 2023 | 19.28M |
| September 30, 2023 | 19.80M |
| June 30, 2023 | 21.17M |
| March 31, 2023 | 22.96M |
| December 31, 2022 | 20.74M |
| September 30, 2022 | 16.54M |
| June 30, 2022 | 16.54M |
| March 31, 2022 | 17.44M |
| December 31, 2021 | 18.38M |
| September 30, 2021 | 15.48M |
| June 30, 2021 | 15.74M |
| March 31, 2021 | 11.52M |
| December 31, 2020 | 11.18M |
| September 30, 2020 | 11.04M |
| June 30, 2020 | 9.987M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.434M |
| December 31, 2019 | 6.026M |
| September 30, 2019 | 7.102M |
| June 30, 2019 | 6.029M |
| March 31, 2019 | 3.355M |
| December 31, 2018 | 4.245M |
| September 30, 2018 | 1.41M |
| June 30, 2018 | 2.157M |
| March 31, 2018 | 10.16M |
| December 31, 2017 | 10.19M |
| September 30, 2017 | 9.689M |
| June 30, 2017 | 9.834M |
| March 31, 2017 | 9.628M |
| December 31, 2016 | 8.862M |
| September 30, 2016 | 7.469M |
| June 30, 2016 | 6.858M |
| March 31, 2016 | 6.857M |
| December 31, 2015 | 6.829M |
| September 30, 2015 | 8.964M |
| June 30, 2015 | 11.54M |
| March 31, 2015 | 11.75M |
| December 31, 2014 | 10.89M |
| September 30, 2014 | 10.24M |
| June 30, 2014 | 9.125M |
| March 31, 2014 | 9.219M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Sionna Therapeutics, Inc. | 21.86M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |